Compare ACADIA Pharmaceuticals Inc. (ACAD) vs F5 Inc (FFIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs F5 Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.45 (market cap $5.07B), while F5 Inc trades at $415.62 (market cap $23.44B). The key difference: F5 Inc is far larger — about 4.6× ACADIA Pharmaceuticals Inc.'s market cap. Which is the better fit depends on your goals.
| ACAD | FFIV | |
|---|---|---|
Market Cap | $5.07B | $23.44B |
Sector | Health | Technology |
52-Week High | $29.41 | $431.26 |
52-Week Low | $20.06 | $223.99 |
Enterprise Value | $4.19B | $22.08B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →
